Novartis: FDA clears Sandoz therapy against opioid abuse

(CercleFinance.com) - The US Food and Drug Administration has granted clearance for new digital therapeutics developed by Novartis' Sandoz and Pear Therapeutics for treating patients with opioid use disorder.


The new digital technology, reSET-O, is intended to increase the retention of patients with opioid use disorder by providing cognitive behavioural therapy in addition to trans-mucosal buprenorphine treatment.

The product is expected to be commercially launched in the US by the end of the year.

According to official statistics, more than 80 percent of patients with opioid use disorder do not receive or seek out care.

Copyright (c) 2018 CercleFinance.com. All rights reserved.